ATRX Rabbit Polyclonal Antibody

Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein and its mutation status may be used as a molecular diagnostic marker within the diff use glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany